Table 2. Results of immunostaining.
| EGFR | pEGFR | HER-2/neu | pAKT | pERK | PTEN | |
|---|---|---|---|---|---|---|
| Primary tumours (n=232) | ||||||
| Evaluablea | 228 | 228 | 230 | 228 | 222 | 224 |
| Positive | 16 (7.0%) | 27 (11.8%) | 12 (5.2%) | 19 (8.3%) | 82 (36.9%) | 155 (69.2%) |
| Negative | 212 (93.0%) | 201 (88.2%) | 218 (94.8%) | 209 (91.7%) | 140 (63.1%) | 69 (30.8%) |
| Second look (n=26) | ||||||
| Evaluablea | 22 | 22 | 22 | 21 | 20 | 19 |
| Positive | 4 (18.2%) | 5 (22.7%) | 1 (4.5%) | 4 (19.0%) | 13 (65.0%) | 16 (84.2%) |
| Negative | 18 (81.8%) | 17 (77.3%) | 21 (95.5%) | 17 (81.0%) | 7 (35.0%) | 3 (15.8%) |
| P-valueb | 0.317 | 0.317 | 1.000 | 0.317 | 0.020 | 0.655 |
| Recurrent disease (n=19) | ||||||
| Evaluablea | 19 | 19 | 18 | 18 | 19 | 18 |
| Positive | 2 (10.5%) | 3 (15.8%) | 2 (11.1%) | 3 (16.7%) | 8 (42.1%) | 17 (94.4%) |
| Negative | 17 (89.5%) | 16 (84.2%) | 16 (88.9%) | 15 (83.3%) | 11 (57.9%) | 1 (5.6%) |
| P-valuec | 0.317 | 0.564 | 0.157 | 0.317 | 0.317 | 0.317 |
Bold signifies P<0.05.
a
Number of evaluable cases (cases with <2 evaluable cores were excluded from the analysis).
b
P-value from Wilcoxon rank sum test for comparison of protein expression between tumour samples from primary surgery and from second look.
c
P-value from Wilcoxon rank sum test for comparison of protein expression between tumour samples from primary surgery and surgery for recurrent disease.